 5MG.png)
GLP 2 (T)
A GLP-2 receptor agonist with applications in metabolic research. Tirzepatide-class peptide studied for body composition and metabolic function.
Compound Profile
Pharmaceutical Data Sheet
 10MG.png)
Mechanism of Action
How GLP 2 (T) Works
Tirzepatide (GLP 2 T) was engineered as a balanced dual agonist at both GIP and GLP-1 receptors, with equal or slightly preferential GIP activity. The GIP receptor component provides incretin amplification and reduces the GI side effect burden of pure GLP-1 agonism, while GLP-1R activity drives appetite suppression and insulin secretion.
- Drives adiponectin release from adipocytes
- Enhances beta-cell preservation and regeneration
- Reduces GI adverse events vs. pure GLP-1
- Promotes fat redistribution via lipolysis
- Reduces food intake via CNS satiety signaling
- Stimulates insulin secretion glucose-dependently
- Decreases glucagon secretion postprandially
- Delays gastric emptying
- Improves peripheral insulin sensitivity
- Reduces fasting and postprandial glucose
- Lowers HbA1c through sustained glycemic control
- Protects pancreatic beta-cell mass
Unlike semaglutide which acts on GLP-1R alone, tirzepatide simultaneously activates GIPR (which historically was thought to promote fat storage but at pharmacological doses drives lipolysis and adiponectin release) and GLP-1R. This co-agonism produces superior weight loss to GLP-1 monotherapy while improving tolerability.
Frias JP et al., N Engl J Med (2021): SURPASS-2 trial demonstrating superiority of tirzepatide over semaglutide.
Preclinical Findings
Research Models
Clinical Data
22.5% Mean Weight Loss — SURMOUNT-1 Trial
The SURMOUNT-1 Phase 3 trial (72 weeks, n=2,539) demonstrated 22.5% mean body weight reduction at the highest dose (15mg), with 63% of participants achieving ≥20% weight loss — surpassing all prior approved weight loss therapeutics.
Jastreboff AM et al., N Engl J Med (2022); SURMOUNT-1 Trial.
Phase 3 RCT, n=2,539, 72-week follow-up
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Nausea and GI side effects are dose-dependent, most common during titration phase
- No increased risk of major adverse cardiovascular events (MACE) in trials
- Rare: injection-site reactions, mild hypoglycemia (when combined with insulin)
- Contraindicated in personal/family history of MTC or MEN2 syndrome
- Regular monitoring of lipase and amylase recommended in long-term protocols
GLP 2 (T) / Tirzepatide clinical data cited relates to the FDA-approved compound analog. For research use only.
About GLP 2 (T)
A GLP-2 receptor agonist with applications in metabolic research. Tirzepatide-class peptide studied for body composition and metabolic function.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
 10MG.png)
 10MG.png)
 5-PACK 10MG.png)